KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (Diluted Average): 2009-2025

Historic Shares Outstanding (Diluted Average) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $258.6 million.

  • Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) fell 0.92% to $258.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.6 million, marking a year-over-year decrease of 0.92%. This contributed to the annual value of $257.9 million for FY2024, which is 1.00% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) is $258.6 million, which was down 0.23% from $259.2 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $261.9 million for Q1 2021, and its period low was $257.9 million during Q1 2022.
  • For the 3-year period, Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $259.7 million, with its median value being $260.3 million (2023).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first dropped by 1.53% in 2022, then increased by 0.93% in 2023.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $259.9 million in 2021, then declined by 0.31% to $259.1 million in 2022, then rose by 0.54% to $260.5 million in 2023, then declined by 1.00% to $257.9 million in 2024, then dropped by 0.92% to $258.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $258.6 million for Q3 2025, versus $259.2 million for Q2 2025 and $259.5 million for Q1 2025.